Boehringer Ingelheim makes first nintedanib filing
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has filed its oral triple angiokinase inhibitor nintedanib (BIBF-1120) in the EU for use in non-small cell lung cancer, following closely the approval there of its leading oncology product Giotrif (afatinib) also for NSCLC. This is nintedanib's first filing, with others planned worldwide.